Drug major Lupin today announced the launch of Desoximetasone Topical Spray, used for treatment of plaque psoriasis, in the US market.
"Lupin's Desoximetasone Topical Spray, 0.25 per cent, is the generic equivalent of Taro Pharmaceuticals U.S.A Inc.'s Topicort Topical Spray, 0.25 per cent. It is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older," the company said in a regulatory filing.
Quoting IQVIA MAT May 2018 data, Lupin said Desoximetasone Topical Spray, 0.25 per cent, had annual sales of approximately USD 18.7 million in the US.
Shares of Lupin were trading 0.71 per cent higher at Rs 820.35 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content